437 results about "Sulfonilamide" patented technology

The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity.　The present invention relates to a substituted sulfonamide compound which is represented by formula (I) or a pharmacologically acceptable salt thereof. A compound according to the present invention, or a pharmacologically acceptable salt thereof, has an agonist activity against OX2R, and is useful as, for example, a therapeutic agent for sleep disorders associated with OX2R (for example, narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia associated with a physical disease, hypersomnia associated with a mental disease, hypersomnia associated with a drug or a substance, circadian rhythm sleep-wake disorders, insufficient sleep syndrome, and extended sleep).

Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.

Provided herein are pharmaceutical compositions, each comprising a phenylsulfonamide, for example, a compound of Formula I, or an enantiomer, a mixture of enantiomers, a mixture of tow ore more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurodegenerative disease.

The invention belongs to the technical field of sulfonamide synthesis, and particularly relates to a green and environment-friendly sulfonamide amidation preparation method. Comprising the following steps: adding chlorosulfonic acid into a reactor, stirring, heating, adding o-nitrochlorobenzene, carrying out staged heat preservation, cooling, and adding thionyl chloride to obtain 2-nitro-4-chlorine sulfonate-chlorobenzene; the method comprises the following steps: separating and filtering 2-nitro-4-chlorine sulfonate-chlorobenzene, adding ammonia water, stirring, preserving heat, and carrying out filter pressing to obtain 2-nitro-4-amine sulfonate-chlorobenzene; the preparation method comprises the following steps: adding liquid caustic soda into 2-nitro-4-amine sulfonate-chlorobenzene, stirring, heating, and adjusting the pH value to obtain 2-nitro-4-amine sulfonate-phenol; the method comprises the following steps: adding water, a catalyst and hydrazine hydrate into 2-nitro-4-amine sulfonate-phenol, heating, stirring, and carrying out filter pressing to obtain 4-sulfonamide-2-amino-phenol. According to the preparation method of sulfonamide, generated tail gas is subjected to falling film absorption treatment, and the product prepared by the preparation method is high in purity.

The invention discloses a preparation method of alplsutentan and an alplsutentan intermediate, alplsutentan is obtained by taking a compound SM1 as a raw material through a one-step method or a multi-step method, and the multi-step method comprises the following steps: reacting the compound SM1 with a compound SM2 to obtain an intermediate I; reacting the intermediate I with 2-[(5-bromo-2-pyrimidinyl) oxy] ethanol to obtain an intermediate II, or reacting the intermediate I with ethylene glycol to obtain an intermediate I-b, and then reacting with 5-bromo-2-chloropyrimidine or 5-fluoro-2-chloropyrimidine to obtain the intermediate II; and finally, removing a protecting group from the intermediate II to obtain alpoxivan. The one-step method comprises the following steps: when X in a compound SM1 is a fluorine atom, the compound SM1 is 5-(4-bromophenyl)-4, 6-difluoropyrimidine, and the compound SM1 reacts with sulfonamide and 2-[(5-bromo-2-pyrimidinyl) oxy] ethanol to directly obtain alpoxivan. The synthesis route is short, and the reaction conditions are mild.

The invention relates to a salt form of a pyrrole sulfonamide acid inhibitor as well as a preparation method and application of the salt form. Specifically, the invention discloses a compound shown as a formula (I), n = 0.1-2.0, and HA is an organic acid or an inorganic acid. The compound has the characteristics of convenience in storage, long-term stability of the product and simple preparation method, meets the industrial production requirements, and meets the development requirements of clinical pharmaceutical preparations. The compound disclosed by the invention can be used for preparing a potassium ion competitive acid blocker and preparing a medicine for treating gastric acid related diseases. # imgabs0 #

Provided in the present application is a compound represented by formula (I), or an enantiomer, a diastereoisomer, a racemate, a tautomer, a stereoisomer, a geometric isomer, a nitrogen oxide, a metabolite or a pharmaceutically acceptable salt, an ester, a solvate, a hydrate, an isotope-labeled compound or a prodrug thereof. The compound represented by formula (I) of the present application has a relatively ideal inhibitory activity with regard to KAT6A and / or KAT6B.

The invention relates to a crystal of a compound as shown in a formula I and a preparation method and application thereof. Specifically, the invention discloses a crystal of a compound shown as a formula I. The crystal form of the crystal is selected from the following groups: crystal form FormA, crystal form FormB, crystal form FormC or crystal form FormD, and n is equal to 0.1-2.0. The crystal form is good in stability, fluidity and moisture absorption resistance, and the preparation method of the crystal form is simple in process, easy to control and suitable for large-scale production. # imgabs0 #

The invention discloses a polyamide composite material as well as a preparation method and application thereof. The polyamide composite material comprises the following components in parts by weight: 28-75 parts of polyamide resin; 3-10 parts of a gas phase reinforcing agent; 8-22 parts of an organic phosphorus flame retardant; 3-12 parts of a synergistic flame retardant; 8 to 32 parts of reinforcing fiber; wherein the gas phase enhancer comprises a compound containing a sulfonamide group, and melem and / or melam, and the mass ratio of the compound containing the sulfonamide group to the melem and / or melam is (0.5-3): 1. According to the invention, the compound containing the sulfonamide group and the melem and / or the melam in a specific mass ratio are added into the polyamide resin to serve as the gas phase enhancer, so that the glowing filament performance of the composite material can be improved, the mechanical property is better, and the mold scale is less.

To provide a resist material which has high sensitivity and improved LWR and CDU regardless of whether it is positive or negative, and a pattern forming method using the same.SOLUTION: The resist material contains a bis-onium salt containing: a divalent anion which has a sulfonic acid anion structure directly bonded to an aromatic group substituted with an iodine atom, and a sulfonimide anion structure or a sulfonamide anion structure bonded to the aromatic group directly or via a linking group containing one or more atoms; and an onium cation.SELECTED DRAWING: None

The invention discloses application of a sulfonamide ionic liquid catalyst system in preparation of cyclic carbonate, sulfonamide ionic liquid comprises cations and anions, and the cations are one or more of tetra-alkyl ammonium ions, tetra-alkyl phosphonium ions and trimethyl hydroxyethyl ammonium ions; the anion is one or more of sulfonamide ions or substituted sulfonamide ions; the sulfonamide ionic liquid is used as a catalyst and is used for catalyzing CO2 to react with an epoxy compound to prepare cyclic carbonate; the catalyst is easy to prepare and high in catalytic activity, under normal pressure, the dosage of the catalyst is 1-3 mol%, the reaction time is 1-48 hours, the reaction temperature is 25-100 DEG C, and a substituted epoxy compound can be converted into corresponding cyclic carbonate with high conversion rate and high selectivity. After the catalyst system is recycled for five times, the catalytic effect is not obviously reduced. Meanwhile, the catalyst system has good universality to substrates, and conversion of various epoxy compounds can be efficiently achieved.

The present invention addresses the problem of providing a novel compound that has OX2R agonist activity.　The present invention relates to a substituted sulfonamide macrocyclic compound represented by formula (I) or a pharmacologically acceptable salt thereof. This compound, or a pharmacologically acceptable salt thereof, has agonist activity against OX2R, and is useful as a treatment agent, etc., for sleep disorders involving OX2R (e.g., narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia associated with a physical disease, hypersomnia associated with a mental disease, hypersomnia associated with a drug or a substance, circadian rhythm sleep-wake disorder, insufficient sleep syndrome, and extended sleep).

A precursor compound and a radioligand for cancer diagnosis and treatment comprises a high-affinity ligand PL for a cancer- associated protein conjugated to a covalent warhead CW for strong or covalent binding to an amino acid sidechain of the cancer-associated protein and a chelator Ch for complexation of a radioisotope or a leaving group LR for substitution with a radioisotope, wherein the covalent warhead CW is configured for quasi-covalent ionic binding using a sulfonic acid group or for covalent binding using a sulfur fluoride exchange (SuFEx) group, a benzotriazole or N-methyl-N- arylmethanesulfonamide leaving group or a malolactone group for strain-release alkylation.

Disclosed herein are compositions and methods for enhancing the ionic conductivity of a solid polymer electrolyte which comprise incorporating an additive that comprises at least one fluorinated sulfonamide compound selected from the group consisting of formulae (1) to (5) into the polymer matrix:and

This invention discloses an analytical method for benzothiazole contaminants, comprising the following steps: detection by high performance liquid chromatography (HPLC), with the following chromatographic conditions: a phenylhexyl column as the stationary phase, mobile phase A being water, mobile phase B being acetonitrile, and gradient elution; wherein the benzothiazole contaminants are at least one of 2-aminobenzothiazole, 2-hydroxybenzothiazole, benzothiazole, 2-methylbenzothiazole, 2-mercaptobenzothiazole, 2,5-dimethylbenzothiazole, 2-cyanobenzothiazole, ethyl 2-carboxylate benzothiazole, 2-chlorobenzothiazole, 2-bromobenzothiazole, 2-methylthiobenzothiazole, phenylthiocyanate, N-tert-butyl-2-benzothiazole sulfenamide, 2-(2-hydroxyphenyl)-benzothiazole, N-cyclohexyl-2-benzothiazole sulfinamide, dibenzothiazole disulfide, and N,N-dicyclohexyl-2-benzothiazole sulfonamide.

The lithium (N-carbonyl) sulfonamide compound is represented by the following formula (I). In formula (I), R 1 and R 2 Each represents an alkyl group having 1 to 10 carbon atoms, an alkenyl group having 2 to 10 carbon atoms, an alkynyl group having 2 to 10 carbon atoms, or an aryl group. 1 and L 2 Each represents a single bond or -O-. Among them, excluding L 1 and L 2 Each is a single bond.

To provide a stable water treatment composition containing an inorganic sterilizing agent having high sterilization power and an azole compound, and a water treatment method using the water treatment composition.SOLUTION: The present invention provides a water treatment composition containing hypobromous acid, a bromine stabilizer, and an azole compound, and having a pH of 13 or more. The bromine stabilizer comprises (A) a sulfonamide compound and (B) a sulfobenzimide compound.SELECTED DRAWING: None

The utility model discloses a flash dryer for producing a pesticide precursor, which relates to the field of pesticide production and comprises a base, a collecting box arranged on one side in the base, a processing tank arranged at the top end of the base, a cooling tank arranged on one side of the processing tank through a discharge pipe, and a precursor processing component arranged on one side of the processing tank and one side of the cooling tank. A precursor smashing assembly is arranged in the base, a screen is arranged on one side of the precursor smashing assembly, and a processing assembly is arranged on one side of the screen. According to the utility model, the precursor processing component is arranged, so that the vortex tube can be utilized to generate high-temperature airflow and low-temperature airflow, the high-temperature airflow can quickly dry sulfonamide, and the low-temperature airflow can cool the dried sulfonamide, so that the cleanliness and the stability of the sulfonamide can be ensured, and the sulfonamide degradation caused by overhigh temperature is avoided; the quality of sulfonamide as a pesticide precursor is influenced.

Provided is a compound represented by formula (I) [in the formula, Q represents a group or the like represented by formula Q1, R2a and R2b are the same or different from each other, and each represents a C1-C6 alkyl group or the like which may be substituted with one or more halogen atoms, and Het represents a group or the like represented by formula Het1], or an N oxide thereof, which has an excellent control effect on harmful arthropods. # imgabs0 #

A novel fused pyrimidine based sulfonamide derivative represented by Formula I, a solvate thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition including the same as an active ingredient, and the uses thereof are disclosed. The novel fused pyrimidine based sulfonamide derivative can effectively suppress the growth of cancer cells and resistance to drugs, which are induced by mutations in the tyrosine kinase domain of epidermal growth factor receptors, or the growth of cancer cells having such resistance.

This invention discloses a method for preparing sulfonamide-modified benzo[a]fluorene-5-one derivatives, using 1,7-enyne and N Using sulfonylaminopyridine salts as raw materials, a series of sulfonated benzo[a]fluorene-5-one compounds were successfully synthesized by catalyzing the sulfonation / cyclization tandem reaction of 1,7-enynes under photocatalytic conditions. This method has excellent functional group tolerance and high economic applicability.

A use of a sulfonamide compound represented by formula (I) or a pharmaceutical composition comprising same in the preparation of a drug for treating pulmonary edema.

The present invention relates to a novel crystalline form of a helicase-primase inhibitor compound, and to pharmaceutical compositions comprising the novel crystalline form, to methods of production of the novel crystalline form, to the crystalline form in medicine and for use in the treatment of herpes viral infections.

The invention provides a crystalline form of N-{4-[2-(2-aminopyrimidin-5-yl)ethynyl]-3- fluoropyridin-2-yl}-5-chloro-2-methoxypyridine-3-sulfonamide characterized by a powder X- ray diffractogram (XRPD) having characteristic peaks at 2Ɵ = 8.6±0.2°, 13.5±0.2°, 22.6±0.2° and 24.7±0.2°. The invention further provides pharmaceutical compositions comprising the 5 crystalline form of the invention and uses of the crystalline form and the compositions. The crystalline form and the compositions are useful for the treatment or prevention of a variety of conditions, particularly cancer.

Rubber compositions including sulfonamides, and golf ball cores made from such compositions are disclosed. The type and concentration of components in the composition affect the properties of cores made therefrom, including, for example, coefficient of restitution and compression, and, thus, can be used to produce golf balls having desirable performance characteristics.

Mcl-1 selective inhibitors, Bcl-2 selective inhibitors, and Mcl-1 / Bcl-2 dual inhibitors and methods of using the same for the treatment of disease are disclosed.

Provided herein are amorphous and crystalline hemisulfate salt forms of the formula.Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.

The invention provides a sulfonamide acetamide compound as well as a preparation method and application thereof. The structure of the sulfonamide acetamide compound is shown as a formula I. The sulfonamide acetamide compound provided by the invention can be used for treating cancers, inflammations and autoimmune diseases. The compound can effectively reduce the protein level of GSPT1 and / or ROR gamma.

The compounds of formula (I) wherein the substituents are as defined in claim 1 and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of these compounds may be used as insecticides. [Formula 1] JPEG2026501744000117.jpg33161